{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:42:44Z","timestamp":1792896164177,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T00:00:00Z","timestamp":1420416000000},"content-version":"vor","delay-in-days":583,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.jbo.2013.01.002","type":"journal-article","created":{"date-parts":[[2013,2,9]],"date-time":"2013-02-09T14:16:09Z","timestamp":1360419369000},"page":"70-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features\u2014An exploratory analysis of placebo-controlled trials"],"prefix":"10.1016","volume":"2","author":[{"given":"Robert E.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ker-Ai","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre P.","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2013.01.002_bib1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.jbo.2013.01.002_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2013.01.002_bib3","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2013.01.002_bib4","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"Journal of National Cancer Institute"},{"key":"10.1016\/j.jbo.2013.01.002_bib5","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2013.01.002_bib6","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.jbo.2013.01.002_bib7","doi-asserted-by":"crossref","unstructured":"Coleman R, de Boer R, Eidtmann H. et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Annal of Oncology 2012;.Oct 9th, E-pub ahead of print.","DOI":"10.1093\/annonc\/mds277"},{"key":"10.1016\/j.jbo.2013.01.002_bib8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncology"},{"issue":"suppl 1","key":"10.1016\/j.jbo.2013.01.002_bib9","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ctrv.2008.03.006","article-title":"Antitumor effects of bisphosphonates: promising preclinical evidence","volume":"34","author":"Guise","year":"2008","journal-title":"Cancer Treatment Reviews"},{"issue":"23","key":"10.1016\/j.jbo.2013.01.002_bib10","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1182\/blood-2011-11-392522","article-title":"Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2013.01.002_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1385\/MO:22:2:195","article-title":"Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline","volume":"22","author":"Mystakidou","year":"2005","journal-title":"Medical Oncology"},{"key":"10.1016\/j.jbo.2013.01.002_bib12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-010-0074-5","article-title":"A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer","volume":"15","author":"Zaghloul","year":"2010","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2013.01.002_bib13","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ijc.24470","article-title":"The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis","volume":"125","author":"Zarogoulidis","year":"2009","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.jbo.2013.01.002_bib14","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jbo.2013.01.002_bib15","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2013.01.002_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.jbo.2013.01.002_bib17","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2013.01.002_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.bjc.6600715","article-title":"Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer","volume":"88","author":"Noguchi","year":"2003","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.jbo.2013.01.002_bib19","first-page":"453","article-title":"Identifying prognostic factors for survival in advanced cancer patients: a prospective study","volume":"13","author":"Lam","year":"2007","journal-title":"Hong Kong Medical Journal"},{"key":"10.1016\/j.jbo.2013.01.002_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3816\/CLC.2008.n.018","article-title":"Population characteristics and prognostic factors in metastatic non-small-cell lung cancer: a Fox Chase Cancer Center retrospective","volume":"9","author":"Paralkar","year":"2008","journal-title":"Clinical Lung Cancer"},{"key":"10.1016\/j.jbo.2013.01.002_bib21","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/cncr.22300","article-title":"Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site","volume":"107","author":"Seve","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2013.01.002_bib22","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archinte.160.6.861","article-title":"Clinical survival predictors in patients with advanced cancer","volume":"160","author":"Vigano","year":"2000","journal-title":"Archives of Internal Medicine (Chicago, IL)"},{"key":"10.1016\/j.jbo.2013.01.002_bib23","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2007.14.9518","article-title":"Assessing 2-month clinical prognosis in hospitalized patients with advanced solid tumors","volume":"26","author":"Barbot","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2013.01.002_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2013.01.002_bib25","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1634\/theoncologist.12-9-1035","article-title":"Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity","volume":"12","author":"Lipton","year":"2007","journal-title":"The Oncologist"},{"key":"10.1016\/j.jbo.2013.01.002_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models of life tables (with discussion)","volume":"34","author":"Cox","year":"1972","journal-title":"Journal of the Royal Statistical Society: Series B (Statistical Methodology)"},{"key":"10.1016\/j.jbo.2013.01.002_bib27","series-title":"The statistical analysis of failure time data","author":"Kalbfleisch","year":"2002"},{"key":"10.1016\/j.jbo.2013.01.002_bib28","series-title":"Statistical models and methods for lifetime data","author":"Lawless","year":"2003"},{"key":"10.1016\/j.jbo.2013.01.002_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","article-title":"Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity","volume":"3","author":"Hirsh","year":"2008","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.jbo.2013.01.002_bib30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/1471-2407-9-272","article-title":"Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity","volume":"9","author":"Major","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbo.2013.01.002_bib31","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/bjc.2011.100","article-title":"Neutrophil\/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer","volume":"104","author":"Chua","year":"2011","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.jbo.2013.01.002_bib32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2013.01.002_bib33","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2013.01.002_bib34","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2013.01.002_bib35","first-page":"2394","article-title":"Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases","volume":"9","author":"Ibrahim","year":"2003","journal-title":"Clinical Cancer Research"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137413000067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137413000067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:15:03Z","timestamp":1761941703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137413000067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S2212137413000067"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2013.01.002","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features\u2014An exploratory analysis of placebo-controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2013.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}